<DOC>
	<DOCNO>NCT01053065</DOCNO>
	<brief_summary>The impact cardiovascular event achieve statin therapy seem mostly attributable cholesterol-lowering effect highly debate contribution lipid-independent pleiotropic effect . However , short-term benefit document patient treated statin acute coronary syndrome clinical setting . These observation strengthen hypothesis additional , so-called pleiotropic action statin . The investigator therefore seek investigate different lipid-lowering strategy ( non-statin therapy , low-dose statin high-dose statin ) affect cellular composition carotid plaque short-term period three month . Specifically investigator try dissect LDL-C lower impact plaque cellular composition compare lipid-independent contribution plaque macrophage smooth muscle cell .</brief_summary>
	<brief_title>The Multicenter Atorvastatin Plaque Stabilization ( MAPS ) Study</brief_title>
	<detailed_description>Patients ( Total Cholesterol ( TC ) range 5.83-7.64 mmol/l ) , never treat lipid lower drug , symptomatic carotid stenosis &gt; 70 % ( NASCET criterion ) , therefore eligible carotid endarterectomy , recruit . All patient enrol within 30 day clinical event , randomize one three treatment group . Each group , compose 20 patient , receive atorvastatin 10 mg/day ( AT-10 group ) , atorvastatin 80 mg/day ( AT-80 group ) , cholestyramine ( Questran , Bristol Myer Squibb ) 8 g/day plus sitosterol ( Unilever ) 2.5 g/day ( C-S group ) three month prior vascular procedure . A placebo group include ethical reason due high cardiovascular risk profile population .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Carotid Stenosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Cholestyramine Resin</mesh_term>
	<mesh_term>Gamma-sitosterol</mesh_term>
	<criteria>Symptomatic carotid stenosis &gt; 70 % ( NASCET criterion ) Eligibility carotid endarterectomy Total cholesterol level 5.83 7.64 mmol/L Never treat lipid lower drug Previous lipid lower therapy Total cholesterol &lt; 5.83 &gt; 7.64 mmol/L Evidence chronic inflammatory disease ( clinical laboratory ) . Patients high risk cerebrovascular event ( i.e . ulcerated carotid plaque , recurrent TIAs ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>Macrophages</keyword>
	<keyword>Carotid artery</keyword>
	<keyword>Statin</keyword>
</DOC>